CorMedix, Inc. (NYSE:CRMD) went up to recover about 885.47% since recording its record low price of $0.86. The stock experienced -3.42% slump, arriving at $8.48 on 4/23/2019. During the day, the stock price traveled from $8.48 to $9.09. This company shares are 147.64% off its target price of $21 and the current market capitalization stands at $205.72M. The recent change has given its price a -7.65% deficit over SMA 50 and -38.1% deficit over its 52-week high. The stock witnessed 2.79% gains, -8.82% declines and 6% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CRMD’s volatility during a week at 6.94% and during a month it has been found around 8.17%.CorMedix, Inc. (CRMD) Top Holders
Institutional investors currently hold around $28 million or 13.4% in CRMD stock. Look at its top three institutional owners: Elliott Associates, L.P. owns $7.32 million in CorMedix, Inc., which represents roughly 3.56% of the company’s market cap and approximately 26.13% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 827,744 shares of the stock are valued at $7.27 million. The third largest holder is Blackrock Inc., which currently holds $4.67 million worth of this stock and that ownership represents nearly 2.27% of its market capitalization.
At the end of December reporting period, 29 institutional holders increased their position in CorMedix, Inc. (NYSE:CRMD) by some 1,258,781 shares, 7 decreased positions by 74,567 and 9 held positions by 1,897,312. That puts total institutional holdings at 3,230,660 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 440,195 shares while 5 institutional investors sold out their entire positions totaling 46,513 shares.CorMedix, Inc. (NYSE:CRMD) Insider Trades
Multiple company employees have indulged in significant insider trading. CorMedix, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO Cook Robert W. has acquired 100 shares of CorMedix, Inc. (CRMD) in the trading session dated Mar. 29, 2019. These shares are worth $935 and were traded at $9.35 each. The SEC filing shows that Baluch Khoso performed a purchase of 2,500 shares. The CEO added these shares by way of transaction on Mar. 26, 2019. The company’s shares were assimilated at $7.55 per share worth to an investment of some $18,875 to the account of Baluch Khoso.
Exec VP of Tech Operations, ARMSTRONG JR. JOHN L., purchased 5,000 common shares of CorMedix, Inc. (CRMD) in the open market. In a transaction dated Mar. 26, 2019, the shares were bought at an average price of $7.73, giving away a sum of $38,650. After this purchase, 69,378 common shares of CRMD are directly owned by the insider, with total stake valued at $588,325.
In the transaction dated Mar. 25, 2019, a great number of shares acquired came courtesy the Exec VP of Tech Operations; ARMSTRONG JR. JOHN L. added a total of 3,000 shares at an average price of $8.45, amounting to approximately $25,350. The insider now directly owns 64,378 shares worth $545,925.
Several analysts have released their opinion on CorMedix, Inc. (NYSE:CRMD), with 0 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.5 average brokerage recommendation [T1].